Navigation Links
QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
Date:8/22/2007

Multicenter Study Enrolls More Than 800 Women to Evaluate QuatRx's

New-Generation Selective Estrogen Receptor Modulator (SERM)

ANN ARBOR, Mich., Aug. 22 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on development and commercialization of compounds to treat endocrine, metabolic and cardiovascular disorders, today announced that it has completed enrollment of a pivotal Phase 3 clinical trial of Ophena(TM) (ospemifene), the company's estrogen-free oral therapy in development for the treatment of vaginal symptoms associated with menopause.

Ophena(TM) is a new-generation selective estrogen receptor modulator (SERM) for postmenopausal vaginal syndrome (PVS), a common condition in postmenopausal women sometimes referred to as vaginal atrophy and characterized by vaginal symptoms such as dryness, irritation and sexual pain. Phase 2 clinical trials with Ophena(TM) demonstrated beneficial effects on vaginal epithelium and bone markers. In addition, in a Phase 2 trial, Ophena(TM) did not induce hot flashes in postmenopausal women when compared to placebo.

Patient enrollment for the randomized, double-blind study has reached 827 post-menopausal women at 80 trial centers throughout the United States. Women participating in the study are treated with either a 30- or 60-mg once daily oral dose of Ophena(TM) or placebo for 12 weeks. The study is the first of two pivotal Phase 3 efficacy trials planned for the compound.

"Completion of enrollment for this first Ophena(TM) Phase 3 trial is a significant development milestone," said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx. "In this pivotal study we are seeking to confirm the beneficial vaginal effects already seen in our Phase 2 program. Millions of women suffer from such post-menopausal symptoms for which there are no oral non-estrogen treatments available. Ophena(TM) is specifically designed to address a major unmet
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Celsion Completes Enrollment in Phase I Liver Cancer Study
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Monitoring Patient Glucose Levels: New Advances in software make it easier
6. Managing Preanalytical Processes for Patient Safety
7. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
8. Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... CHICAGO, Ill. , July 23, 2014 ... OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ... OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. ... second-quarter 2014 financial results on Friday, July 25, 2014, before ... webcast of the earnings conference call at 8 a.m. Central ...
(Date:7/23/2014)... 2014 /PRNewswire-iReach/ -- The Centers for Medicare & Medicaid ... Network-Quality Improvement Organization (QIN-QIO) contract to a partnership led ... Effective August 1, WVMI will launch Quality Insights Quality ... Pennsylvania , Delaware ... The Network will engage providers and the community in ...
(Date:7/23/2014)... 2014 Research and Markets   ... Electrophysiology Ablation Catheters Market 2014-2018" report to ... Catheter ablation is a minimally ... electrical pathways from sections of the heart that ... arrhythmias). Cardiac arrhythmias can be of several types, ...
Breaking Medicine Technology:AbbVie to Host Second-Quarter Earnings Conference Call 2AbbVie to Host Second-Quarter Earnings Conference Call 3AbbVie to Host Second-Quarter Earnings Conference Call 4AbbVie to Host Second-Quarter Earnings Conference Call 5AbbVie to Host Second-Quarter Earnings Conference Call 6Announcing a New Regional Approach to Medicare Quality Improvement 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3
... Truphatek has successfully enticed one of the best known professionals in ... , Dan White , formerly of ... a new US subsidiary of Truphatek http://www.truphatek.com/ ... I may be reached after this week at 573-240-0002 or by e-mail ...
... , NEWARK, Calif., Oct. 6 Extending its reach ... North America, Inc. has signed ... distribute its perfluoroelastomer sealing components and provide local applications ... are integral in the ultraclean manufacturing of semiconductors, solar ...
Cached Medicine Technology:New Places and People - Truphatek opens USA subsidiary 2New Places and People - Truphatek opens USA subsidiary 3Applied Seals North America Extends Global Network With Addition of Distributor in Europe 2
(Date:7/23/2014)... Dallas, TX (PRWEB) July 23, 2014 ... could be diminished using non-surgical techniques, according to a ... of puffy eyes serum sold in the U.S. is ... http://cherrynews.com/best-nourishing-eye-serum . , The complimentary guide that is ... consumers who struggle with under eye puffiness. While surgical ...
(Date:7/23/2014)... near Sellafield or Dounreay since the 1990s are not ... research published in the British Journal of Cancer ... Research Group at the University of Oxford and from ... among those who were under 25 and living near ... in cancer incidence from 1991-2006 between those living near ...
(Date:7/23/2014)... Oklahoma (PRWEB) July 23, 2014 ... America’s leading provider of in-home care for seniors, ... Longevity Webinar Series featuring experts in a wide ... webinar will feature licensed clinical social worker and ... most common causes of caregiver stress and ways ...
(Date:7/23/2014)... 2014 In preparation for National Health ... Treatment Group is providing tips on choosing a reputable ... ever since man first figured out the process of ... existed since shortly thereafter. Its basis lies in the ... developing a way to combat that problem while monetizing ...
(Date:7/23/2014)... HealthDay Reporter WEDNESDAY, July 23, 2014 (HealthDay ... exposed to some form of childhood trauma than their civilian ... to apply solely to military men, not women. The ... for concern, given that early childhood exposure to various forms ... has been linked to a higher adult risk for depression, ...
Breaking Medicine News(10 mins):Health News:Puffy Eyes Serum Explored in Complimentary Guide Released at Consumer News Website 2Health News:Oklahoma Home Care Assistance Hosting Caregiver Mindfulness Webinar Tomorrow 2Health News:Oklahoma Home Care Assistance Hosting Caregiver Mindfulness Webinar Tomorrow 3Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3Health News:Many U.S. Male Soldiers Had Troubled Childhoods, Study Finds 2Health News:Many U.S. Male Soldiers Had Troubled Childhoods, Study Finds 3
... cancer is the most common cancer diagnosed among men in ... There are several // treatment options, but new research shows ... , Doctors hope that the drug -- finasteride ... smaller doses, it’s commonly known as Propecia for baldness. It ...
... A new study finds angioplasty should be the treatment ... hospital they initially go to doesn’t offer angioplasty// services ... for treatment. ,Research has shown heart attack patients ... open up the clogged blood vessel that caused the ...
... New research reports, patients who were treated for depression ... vitamin B12 in their blood.// ,An increasing amount ... B and depression, but the specifics have not been ... relationship of vitamin B12 and the treatment of depression. ...
... A new study shows people who suffer from migraine headaches ... which are areas of the brain where the tissue has ... ages 30 to 60. They grouped the patients into categories ... no visual difficulties. A control group was also included in ...
... new study finds people who participated in a cardiac-rehab program ... rate // as those of the same age and sex ... about half of the deaths that occurred among patients in ... cardiac-rehab program. ,The investigation involved about 1,800 patients. Nearly ...
... from extremely low body fat whether due to strenuous ... from treatment with the appetite-and-weight-regulation hormone leptin.// The study ... instances of infertility. ,Leptin is produced in fat ... then travels to the brain and plays a role ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: